301 – 310 of 548
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
(
- Contribution to journal › Scientific review
-
Mark
18
F-Flortaucipir in TDP-43 associated frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
(
- Contribution to journal › Article
-
Mark
Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake
(
- Contribution to journal › Article
-
Mark
Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline
(
- Contribution to journal › Article
-
Mark
Parkinson's disease : Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study
(
- Contribution to journal › Article
-
Mark
Correlation of in Vivo [18F]Flortaucipir with Postmortem Alzheimer Disease Tau Pathology
(
- Contribution to journal › Article
-
Mark
Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease : Cross-validation study of practical algorithms
(
- Contribution to journal › Article
- 2018
-
Mark
Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
(
- Contribution to journal › Article